

### Confirmed Plenary Speakers (to Date)

**QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases**

Dr Atwood CHEUNG  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

**The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis**

Dr Andrew DILGER  
(BRISTOL-MYERS SQUIBB, Princeton, United States)

**First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases**

Dr Riccardo GIOVANNINI  
(BOEHRINGER INGELHEIM, Biberach, Germany)

**Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other**

Dr Uwe GREETHER  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

**The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations**

Dr Wooseok HAN  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)

**Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH**

Dr Naoyoshi NOGUCHI  
(SCOHIA PHARMA, INC., Fujisawa, Japan)

**Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma**

Dr Matthew W. D. PERRY  
(ASTRAZENECA, Gothenburg, Sweden)

**Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy**

Dr Norbert SCHMEES  
(BAYER PHARMACEUTICALS, Berlin, Germany)

**GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)**

Dr Fredrik ZETTERBERG  
(GALECTO BIOTECH, Gothenburg, Sweden)

**Confirmed Speakers**

# EFMC-ISM Virtual Event 2020

## Programme

### Monday September 7, 2020

#### EFMC-ISM Virtual Event 2020 - Day 1

- 17:00**    **Opening Address by EFMC President**  
Dr Yves P. AUBERSON  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 17:10**    **Session Chair**  
Prof. Karl-Heinz ALTMANN  
(ETH ZÜRICH, Zürich, Switzerland)
- 17:15**    **Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy**  
Dr Norbert SCHMEES  
(BAYER PHARMACEUTICALS, Berlin, Germany)
- 17:45**    **Discovery of AZD8154, a Dual PI3K?? Inhibitor, as an Inhaled Treatment for Asthma**  
Dr Matthew W. D. PERRY  
(ASTRAZENECA, Gothenburg, Sweden)
- 18:15**    **The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis**  
  
Dr Andrew DILGER  
(BRISTOL-MYERS SQUIBB, Princeton, United States)
- 18:45**    **QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases**  
Dr Atwood CHEUNG  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)
- 19:15**    **Closing Remarks**  
Prof. Karl-Heinz ALTMANN  
(ETH ZÜRICH, Zürich, Switzerland)
- 19:20**    **End of Day 1**

# EFMC-ISMC Virtual Event 2020

## Programme

**Tuesday September 8, 2020**

EFMC-ISMC Virtual Event 2020 - Day 2

- 16:00 Opening Address by EFMC-ISMC Chairman**  
Prof. Karl-Heinz ALTMANN  
(ETH ZÜRICH, Zürich, Switzerland)
- 16:10 Session Chair**  
Dr Yves P. AUBERSON  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 16:15 Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH**  
Dr Naoyoshi NOGUCHI  
(SCOHIA PHARMA, INC., Fujisawa, Japan)
- 16:45 The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations**  
Dr Wooseok HAN  
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Songpa-gu, Korea, South)
- 17:15 GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)**  
Dr Fredrik ZETTERBERG  
(GALECTO BIOTECH, Gothenburg, Sweden)
- 17:45 First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases**  
Dr Riccardo GIOVANNINI  
(BOEHRINGER INGELHEIM, Biberach, Germany)
- 18:15 Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other**  
Dr Uwe GREETHER  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)
- 18:45 Closing Remarks, EFMC-ISMC 2021 and EFMC Events**  
Prof. Karl-Heinz ALTMANN (ETH ZÜRICH, Zürich, Switzerland)  
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
- 19:00 End of the EFMC-ISMC Virtual Event 2020**